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Endometrial cancer is the most common female genital tract malignancy in the United States. Type I endometrial cancer is usually
diagnosed at an early stage, and has a good prognosis. Type II is very aggressive, and is responsible for most uterine cancer relapses
and deaths. Uterine serous adenocarcinomas (USC) constitute the majority of Type II variants. They have a higher propensity for
lymph node and distant metastases. They are frequently aneuploid and associated with p53 mutations. erbB2 overexpression in
USC has been described. The incidence, which is higher in African Americans, ranges from 18–80%. erbB2 overexpression was
foundtobeassociatedwithhigherstage,chemoresistance,andworsesurvival.TrastuzumabahumanizedmAbwasapprovedbythe
FDA for treatment of breast cancers that overexpress erbB2 in combination with standard chemotherapy. Evidence of trastuzumab
activity in USC has been reported in vitro, as well as in case reports of advanced and recurrent cases. Promising results were
obtained in these heavily pretreated patients either with trastuzumab alone or in combination with chemotherapy. This supports
the hypothesis that trastuzumab may very well be an attractive and viable treatment option for advanced stage USC tumors that
overexpress the erbB2, and is worthy of further study.
1.EndometrialCancer
Endometrial cancer is the most common female genital tract
malignancy in the United States, with an incidence of 40100
new cases and 7470 deaths annually [1] .T y p eIe n d o m e t r i a l
cancer, which has an endometrioid histology, is associated
with obesity, estrogen excess, and is heralded by endometrial
hyperplasia. It is usually diagnosed at an early stage and has
a good prognosis. On the other hand, Type II endometrial
cancer is a very aggressive variant of the disease and is
responsible for about 50% of all uterine cancer relapses and
most deaths [2].
2. Uterine Serous Cancer
Uterine serous adenocarcinomas (USC) constitute the ma-
jority of Type II variants, and about 10% of all endometrial
cancers [3]. USC has a higher propensity for lymphovascular
invasion, and intraperitoneal as well as extraabdominal
spread, than endometrioid carcinoma. It also has a signif-
icantly greater incidence of pelvic and para-aortic lymph
node metastases [4]. At the time of presentation, approx-
imately 60 to 70 percent of women with USC will have-
disease spread outside of the uterus [3]. Overall 1-year-,
2-year-, and 5-year-survival in USC is 84%, 71%, and 54%,
respectively. This is compared to a respective overall survival
of94%,89%,and80%inendometrioidadenocarcinoma[5].
InaYaleseries,therewasnosurvivaldiﬀerencebetweenstage
I patients who had 10–50% of the endometrial carcinoma
composed of USC compared with those with more than 50%
USC [6].
Surgical staging remains the mainstay of treatment of
USC, as the majority of patients with disease clinically con-
ﬁned to the uterus will be upstaged (57–70%) Staging entails
a hysterectomy, bilateral salpingo-oopherectomy, omentec-
tomy, bilateral pelvic lymphadenectomy, para-aortic node2 Obstetrics and Gynecology International
sampling, and peritoneal cytology obtained upon entry into
the abdominal cavity. Adjuvant therapy is usually recom-
mended [7].
A Gynecologic Oncology Group trial (GOG 94) reported
a 35% 5-year-disease-free survival when 31 women with
stages I and II USC received adjuvant postoperative whole
abdomen radiation therapy. Some institutional experiences
suggest that whole abdomen radiation therapy may be
beneﬁcial. Others have not found it to be eﬀective [6, 8, 9].
Martin et al. hypothesized that USC radiation resistance
may be attributed to p53 overexpression through the evasion
of radiation-induced apoptosis. Indeed, radioresistance of
breast cancer has been associated with erbB2 overexpres-
sion [9]. The Yale experience suggests that vaginal apex
brachytherapy plays an important part in the management
ofthedisease,asnorecurrencespresentedatthevaginalapex
among 43 stage I patients with early stage USC treated with
this technique [6].
Platinum-based chemotherapy has been routinely em-
ployed in the management of both early and advanced
stages of USC. Although conﬂicting data exist, a Yale series
suggested that carboplatin and paclitaxel in surgical stage I
USC should be employed as part of the routine method of
management of the disease [6]. Only one of 29 stage IA–
IC patients (3.4%) recurred, who received platinum-based
chemotherapy, whereas 20 out of 32 (62.5%) who did not
receive chemotherapy recurred [6] .R e c e n t l y ,as t u d yo f2 5
stage I-II USC patients treated at Sloan-Kettering memorial
hospital with acombination of carboplatin/paclitaxel and
vaginal brachytherapy found comparable results [10]. The
overallsurvivalofwomenwithUSC,however,remainsabout
30%. The survival of women with stages I-II USC is 35–50%
and for stages III-IV is 0–15% [11]. Overall recurrence rate is
about 80%, and new therapeutic modalities are still needed
[12].
3.erbB2 inUSC
WhereasUSCdoesnotsharethetypicalriskfactorsknownto
inﬂuence its endometrioid counterpart, several unique prog-
nosticators have been identiﬁed in this variant. Commonly
seen in older, thin, and nulliparous patients, and in African
American women, the molecular biology of USC is also
distinctive. The tumors, infrequently express estrogen (ER)
and progesterone (PR) receptors, are frequently aneuploid,
and the majority (90%) are associated with p53 mutations
[13]. P53 mutation is known to enhance the aggressiveness
of the disease by modulating pathways of proliferation and
apoptosis.
In 2002, Santin et al. reported for the ﬁrst time on erbB2
overexpression in USC specimens in vitro. Eight out of 10
specimens stained heavily (2+, 3+) for erbB2 by immunohis-
tochemistry. Furthermore, USC cell lines expressed 10-fold
higher erbB2 levels than erbB2-positive ovarian and breast
cancer cell lines by ﬂowcytometry. The sensitivity of those
cell lines to antibody dependent cytotoxicity in vitro was also
demonstrated in this study [14].
The same group then used oligonucleotide microarrays
to analyze gene expression proﬁling of USC and normal
endometrial cells in culture. Among 529 diﬀerentially
expressed genes, c-erbB2 gene which, encodes for the erbB2
receptor, was found to be highly expressed in USC [15].
In later publications, the same group, as well as others,
have shown that erbB2 receptor is expressed in 18–62% of
USC. USC overexpression and ampliﬁcation was found to
be associated with chemoresistance, higher stage, and worse
overall survival [12, 14, 16, 17]. Indeed, erbB2 gene ampli-
ﬁcation by FISH was observed more frequently in African
American patients compared to Caucasians (P = 0.02), and
to be associated with a worse prognosis in this subgroup of
patients (P = 0.01). It was associated with a shorter overall
survival in all patients tested (P = 0.0008) [18].
The correlation between erbB2 overexpression by im-
munohistochemistry (IHC) and erbB2 gene ampliﬁcation
by ﬂuorescent in situ hybridization (FISH) was addressed
in two further studies. In one study, moderate to strong
expression of erbB2 was found in 16 (62%) of 26 USC
samples evaluated, with 7 (27%) samples showing moderate
staining (2+) and 9 (35%) showing strong staining (3+).
Ampliﬁcation of the erbB2 gene by FISH was observed in 11
(42%) of the 26 samples. Protein overexpression and gene
ampliﬁcation were found to correlate in 100% (9 of 9) of
the 3+ tumors and in 29% (2 of 7) of the 2+ tumors. None
of the 10 USC samples that scored 0 or 1+ by IHC tested
positive for gene ampliﬁcation by FISH [19]. In another
study, strong erbB2 membrane staining (3+) of USC samples
was observed in 16.6% (2 of 12) of samples tested. There
was perfect correlation with gene ampliﬁcation by FISH, as
well as messenger RNA expression by quantitative real time
reverse transcription (RT) polymerase chain reaction (PCR)
[16]. Interpretation of IHC results follow the breast cancer
guidelines, where a 3+ score is deﬁned as heavy staining of
the cell membrane in more than 10% of tumor cells, 2+
is deﬁned as moderate staining in more than 10% of cells,
a n das c o r eo f1 +o r0i sd e ﬁ n e da sl i g h to rn om e m b r a n e
staining, respectively. A score of 1+ or 0 indicates a negative
test. We have also adopted the same treatment strategy used
in breast cancer, where conﬁrmation of an IHC 2+ score by
FISH testing, performed before treatment with trastuzumab,
is begun.
A Gynecologic Oncology Group (GOG) analysis of 234
samples of advanced and recurrent endometrial cancer
found erbB2 overexpression and gene ampliﬁcation in 44%
and 12% of cases, respectively. There was a signiﬁcant
increased frequency of overexpression in USC versus all oth-
ers (61% versus 41%) [20]. Neither protein overexpression
nor gene ampliﬁcation predicted overall survival, however,
the study included highly advanced cases, and the analysis
combined endometrioid and serous cancers (i.e., Type I and
Type II endometrial carcinomas).
4.erbB2
erbB2 is a member of the erbB receptor tyrosine kinase. This
is a family of 4 transmembrane glycoproteins (EGFR/erbB1,
erbB2, erbB3, and erbB4) that are expressed on epithelial,
mesenchymal, and neuronal cells. erbB receptors are acti-
vated in response to binding with 11 ligands produced inObstetrics and Gynecology International 3
an autocrine fashion in the individual cells or a paracrine
fashion in the surrounding tissue. Ligand binding results
in dimerization of the receptor either with a twin receptor
(homodimerization)orwithoneofitssiblings(heterodimer-
ization). This leads to phosphorylation of the intracellular
tyrosine kinase residues which serve as docking sites for
various eﬀectors and transcription factors that ultimately
modulate various biological responses, such as proliferation,
survival, migration, and diﬀerentiation. Diﬀerent ligands
bind speciﬁc receptors based on their binding aﬃnities. This
results in a variety of dimerization combinations and, in
turn, activation of diverse intracellular pathways. It is note-
worthy that erbB2 has no deﬁned ligand and, due to its con-
formation design, is the preferred dimerization partner of
all other erbB receptors. Furthermore, an erbB2 heterodimer
is characterized by a stronger and more diverse signaling
potential than other erbB dimers [21]. erbB2 overexpression
was, indeed, found in various cancers (including breast,
ovarian, and endometrial) to be associated with cancer cell
proliferation, poor survival, and resistance to therapy [12,
22–25].
5.Trastuzumab
It is, therefore, not surprising that erbB2 has been the target
of immunotherapy by monoclonal antibodies (mAb) in a
number of cancers. Most notably, 25 to 30 percent of breast
cancers overexpress erbB2, and have been targeted for mAb
therapy. Trastuzumab (Herceptin, Genentech, South San
Francisco, Calif) a humanized mAb of the IgG1 family, was
approved by the FDA in 1998 for treatment of metastatic
breast cancers that overexpress erbB2 in combination with
standard chemotherapy.
Whereas Trastuzumab is alleged to inhibit downstream
signal transduction, ultimately modulating proliferation and
apoptosis, its principal mechanism of action is believed to be
through recruiting host immune cells (Natural Killer cells),
and setting oﬀ an antibody-dependent cell-mediated cy-
totoxicity (ADCC) process [26–28]. This is dependent on
receptor overexpression. Based on the breast cancer model,
primary USC cell lines in culture challenged with peripheral
blood lymphocytes in the presence of Herceptin in a stan-
dard 5-hour-chromium-release cytotoxicity assay endured
signiﬁcant killing, up to 75%, compared to control. This was
mainly attributed to Herceptin-induced antibodydependent
cell-mediated cytotoxicity reaction. Herceptin also had an
anti-proliferative eﬀect on those cell cultures [14, 29].
6.TrastuzumabinBreast Cancer
In a landmark phase III study, of advanced breast cancer,
by Slamon et al. [30], trastuzumab was found to reduce the
relative risk of death by 20% at a median followup of 30
months in the group of patients who received chemotherapy
andtrastuzumabcomparedtothegroupwhoreceivedchem-
otherapy alone. The addition of trastuzumab to either an-
thracyclines plus cyclophosphamide or a taxane was also as-
sociated with a longer time to disease progression, a high
rate of objective response, and a longer duration of response
[30]. Eligible patients were erbB2 2+ and 3+ overexpressors
as determined by immunohistochemistry (IHC). Greater
eﬃcacy was noted in IHC 3+ patients compared to the over-
all population. Subsequently, trastuzumab was consistently
shown to signiﬁcantly improve disease free survival (up to
50%) in multiple other studies when used in combination
with multiple other chemotherapies, including taxanes and
platinum compounds [31, 32]. The National Surgical Adju-
vant Breast and Bowel Project (NSABP) trial B-31 and the
North Central Cancer Treatment Group trial N9831 results
led to the approval of adjuvant trastuzumab therapy in
operable breast cancer. The use of trastuzumab plus chem-
otherapy in this setting was associated with a 33% reduction
in the risk of death (P = 0.015) [33].
The sentinel indication for Herceptin therapy, namely,
erbB2 positivity, was determined in various trials by either
IHC or ﬂuorescent insitu hybridization (FISH). While IHC
shows erbB2 receptor overexpression in cancer specimens,
FISH conﬁrms erbB2 gene ampliﬁcation. The concordance
of those two techniques was retrospectively analyzed and
was generally found to be 82% [34]. Concordance between
IHC 3+ and FISH-positive tumors was even greater (89%).
However, concordance between IHC 2+ tumors and FISH
positivity was 24%, begging the question if conﬁrmation of
IHC 2+ by FISH would ensure better results.
7. TrastuzumabinEndometrial Cancer
A phase II study of single-agent trastuzumab in advanced/re-
current endometrial cancer patients of any histology has
recently been reported from the GOG [35]. This study was
not able to demonstrate single agent activity of trastuzumab
against endometrial carcinoma patients harboring tumors
with HER2/neu overexpression. Such results, however, have
recently been challenged due to the many shortcomings in
the design of the GOG181b study [36]. Moreover, evidence
of trastuzumab clinical activity in a handful of heavily
pretreated endometrial carcinoma patients has been recently
reported as case reports in the medical literature. Consistent
with this view, Santin et al. recently reported on two
endometrial cancer patients treated with Herceptin. The ﬁrst
case had a stage IIIA platinum refractory G3 endometrioid
tumor with IHC 3+ erbB2 overexpression. The second case
hadastageIIICUSCthatpersistedaftersurgeryandadjuvant
pelvic as well as extended ﬁeld radiation. This patient had
an IHC 2+ erbB2 overexpression. Both cases received salvage
treatment with Herceptin with chemotherapy in the former,
and as a single agent in the latter. Both cases achieved
signiﬁcant partial response, stable disease, and a substantial
sustained decrease in CA125 [37]. In another case report,
Jewell et al. reported similar success with Herceptin therapy
in combination with chemotherapy in a 72-year-old patient
with stage IIIA grade 2 endometrioid adenocarcinoma that
recurred after surgery and adjuvant radiation therapy. The
tumor showed IHC 3+ erbB2 overexpression [38]. Finally,
Villella et al. reported on two recurrent USC patients with
advanced disease and 3+ staining by IHC. When treated with
Herceptin,onepatientachievedacompleteresponse,andthe
other had stable disease [39]. Trastuzumab therapy was well4 Obstetrics and Gynecology International
tolerated in these patients and, consistent with these results,
the single agent use of trastuzumab in a Phase II study of
advanced/recurrent endometrial cancer patients by the GOG
did not identify any new toxicities or an increased frequency
of currently reported toxicities of trastuzumab [35]. In
this regard, the major potential toxicities associated with
trastuzumab use may include infusion reactions, embryo-
fetal toxicity, pulmonary toxicity, and cardiotoxicity. Impor-
tantly, the incidence of congestive heart failure and cardiac
dysfunction in breast cancer patients have been shown to
range from 0.4–3.8% in the major adjuvant trastuzumab
trials and to be higher in patients receiving trastuzumab with
anthracycline containing chemotherapy regimens [30–33].
The above data support the hypothesis that Herceptin
may very well be an attractive and viable treatment option
for advanced stage USC tumors that overexpress the erbB2
receptor. This constitutes the merit of a multi-institutional
randomizedtrialduetoopensoonintheUnitedStates(clini-
caltrials.gov/ct2/show/NCT01367002). The primary objective
of this phase II study is to evaluate whether the addition
of trastuzumab (Herceptin) to paclitaxel and carboplatin
chemotherapy improves progression free survival (PFS)
when compared to paclitaxel and carboplatin alone in stages
III-IV and recurrent USC patients overexpressing HER2/neu
at 3+ level by IHC or positive by FISH. The secondary
objectives of the study include (a) assess objective response
rate (ORR), (b) assess overall survival (OS), and (c) assess
the safety proﬁle of trastuzumab in USPC patients. The
exploratory/correlative objectives of the study include (a)
determine peripheral blood natural killer (NK) cell numbers
and activity in HER2/neu+ USC patients to provide a
basis for assessing the possible therapeutic contributions of
immune mechanisms of action of trastuzumab, (b) study
HER2/neu extracellular domain (ECD) circulating levels in
theplasmaofUSCpatientsoverexpressingHER2/neubefore,
during and after treatment to elucidate whether changes in
HER2/neu ECD would predict response to trastuzumab, and
(c) determine whether CA-125 levels correlate with disease
activity in advanced and/or recurrent disease. As predicted
in 2003, the Achilles heel of USC may soon be exposed [40].
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